BR112021019099A2 - Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios - Google Patents

Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios

Info

Publication number
BR112021019099A2
BR112021019099A2 BR112021019099A BR112021019099A BR112021019099A2 BR 112021019099 A2 BR112021019099 A2 BR 112021019099A2 BR 112021019099 A BR112021019099 A BR 112021019099A BR 112021019099 A BR112021019099 A BR 112021019099A BR 112021019099 A2 BR112021019099 A2 BR 112021019099A2
Authority
BR
Brazil
Prior art keywords
compounds
treatment
pharmaceutical compositions
inflammatory disorders
methods
Prior art date
Application number
BR112021019099A
Other languages
English (en)
Inventor
John Robert Newsome Gregory
Gilles Babel Marielle
Oscar Mammoliti
Christophe Xavier Brys Reginald
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112021019099A2 publication Critical patent/BR112021019099A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios. a presente invenção refere-se a compostos de acordo com a fórmula i, em que r1, r2 e cy são como aqui definidos. a presente invenção se refere a compostos, métodos para a produção dos referidos compostos, composições farmacêuticas compreendendo os referidos compostos e métodos para a profilaxia e/ou tratamento de doenças inflamatórias, doenças autoimunes, dor, fibrose e/ou doenças proliferativas pela administração dos referidos compostos.
BR112021019099A 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios BR112021019099A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
BR112021019099A2 true BR112021019099A2 (pt) 2021-11-30

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019099A BR112021019099A2 (pt) 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios

Country Status (13)

Country Link
US (1) US20220296573A1 (pt)
EP (1) EP3947374A1 (pt)
JP (1) JP2022526553A (pt)
KR (1) KR20210143905A (pt)
CN (1) CN113677678A (pt)
AU (1) AU2020252900A1 (pt)
BR (1) BR112021019099A2 (pt)
CA (1) CA3134732A1 (pt)
GB (1) GB201904375D0 (pt)
IL (1) IL286688A (pt)
MX (1) MX2021011574A (pt)
SG (1) SG11202110643YA (pt)
WO (1) WO2020200898A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911652A1 (en) * 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
KR20230059584A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418965C (zh) * 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
ES2824723T3 (es) * 2013-03-14 2021-05-13 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
AU2015205348A1 (en) * 2014-01-10 2016-07-28 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
CN108473498B (zh) * 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途

Also Published As

Publication number Publication date
SG11202110643YA (en) 2021-10-28
MX2021011574A (es) 2021-10-13
WO2020200898A1 (en) 2020-10-08
KR20210143905A (ko) 2021-11-29
CA3134732A1 (en) 2020-10-08
JP2022526553A (ja) 2022-05-25
IL286688A (en) 2021-10-31
AU2020252900A1 (en) 2021-11-25
EP3947374A1 (en) 2022-02-09
CN113677678A (zh) 2021-11-19
GB201904375D0 (en) 2019-05-15
US20220296573A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112016012734A8 (pt) composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112018067312A2 (pt) compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA201891710A1 (ru) Терапевтические соединения
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
EA201792469A1 (ru) Циклические соединения
BR112021019110A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112022001002A2 (pt) Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]